In breast cancer treatment, evaluating biomarkers—estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)—is strongly recommended in clinical guidelines, as they serve as key predictors of treatment outcomes [1]. Here, PGR is linked to breast carcinoma.